Home Ingredients D-Chiro-Inositol
Women's HealthMetabolic HealthFertility

D-Chiro-Inositol

Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

D-chiro-inositol (DCI) is one of nine inositol stereoisomers and the rarer counterpart to myo-inositol (MI), which dominates in most tissues. The body converts MI to DCI tissue-specifically via insulin-stimulated epimerase activity, and DCI participates in inositol-phosphoglycan (IPG) second messengers downstream of insulin. The foundational 1999 trial by Nestler et al. in the New England Journal of Medicine established DCI as a candidate insulin-sensitizer for polycystic ovary syndrome (PCOS). Subsequent work has refined the model — high-dose DCI alone may paradoxically worsen ovarian function, leading to the Carlomagno-developed 40:1 myo-inositol:D-chiro-inositol combination protocol that is now the most-studied formulation.

Studied Dose DCI alone: 600-1,200 mg/day (older trials). Modern 40:1 MI:DCI: 4 g myo-inositol + 100 mg D-chiro-inositol per day, divided.
Active Compound D-chiro-inositol (a stereoisomer of inositol); often paired with myo-inositol in 40:1 ratio formulations.

Benefits

Supports Ovulation in PCOS

D-chiro-inositol supplementation has been studied for restoration of ovulation in women with PCOS, with the foundational NEJM trial showing 86% ovulation rate on DCI vs 27% on placebo over 6-8 weeks in obese women.

Supported by Trial 1, Trial 2

Supports Insulin Sensitivity

DCI participates in inositol-phosphoglycan second messengers downstream of insulin and was developed as a candidate insulin-sensitizer for women with PCOS-associated insulin resistance.

Supported by Trial 1, Trial 2

Modulates Androgens in PCOS

DCI treatment reduces circulating free testosterone and improves serum androgen profiles in women with PCOS, with effects observed in both obese and lean populations in early clinical work.

Supported by Trial 2, Trial 1

Optimal in 40:1 Ratio with Myo-Inositol

Modern protocols combine myo-inositol and D-chiro-inositol in a 40:1 ratio, mirroring the physiological plasma ratio in reproductively healthy women. High-dose DCI alone may paradoxically reduce oocyte quality.

Supported by Trial 3, Trial 2

May Support Metabolic Markers

DCI treatment has been associated with reductions in blood pressure, triglycerides, and serum insulin in lean and obese women with PCOS, suggesting broader metabolic effects beyond reproductive endpoints.

Supported by Trial 2, Trial 1

Mechanism of action

1

Inositol-Phosphoglycan (IPG) Second Messengers

DCI is incorporated into inositol-phosphoglycans that act as second messengers downstream of insulin receptor activation, supporting glucose disposal and insulin-mediated signaling.

2

Tissue-Specific MI-to-DCI Conversion

Insulin stimulates epimerase activity that converts myo-inositol to D-chiro-inositol in a tissue-specific manner. In PCOS ovaries, conversion may be elevated, leading to relative MI deficiency — the rationale for the 40:1 combination protocol.

3

Aromatase Modulation

At high doses, DCI may inhibit aromatase (estrogen-synthesizing enzyme), an effect that contributes to its androgen-lowering action but can also worsen ovarian function if MI is depleted.

4

Androgen Pathway Modulation

DCI supplementation lowers circulating free testosterone in PCOS, likely through combined effects on insulin signaling, aromatase activity, and downstream ovarian steroidogenesis.

Clinical trials

1
D-Chiro-Inositol for Ovulation in Obese PCOS — Foundational Trial

Randomized, double-blind, placebo-controlled trial of D-chiro-inositol (1,200 mg/day) vs placebo for 6-8 weeks in obese women with PCOS. Outcomes: ovulation rate (serum progesterone), serum androgens, oral glucose tolerance.

44 obese women with PCOS; 6-8 week intervention.

Ovulation occurred in 86% of women on DCI vs 27% on placebo. DCI also reduced serum free testosterone, blood pressure, and triglycerides while improving glucose-tolerance parameters. Established DCI as a candidate insulin-sensitizer in PCOS.

2
D-Chiro-Inositol in Lean Women with PCOS

Randomized, placebo-controlled trial of D-chiro-inositol (600 mg/day) vs placebo for 6-8 weeks in lean women with PCOS. Outcomes: serum insulin, androgens, ovulation, blood pressure, triglycerides.

20 lean women (BMI 20-24.4 kg/m²) with PCOS.

DCI reduced plasma insulin and free testosterone, lowered systolic and diastolic blood pressure and triglycerides, and induced ovulation in 60% vs 20% in placebo. Extended the PCOS finding from obese to lean phenotypes.

3
40:1 Myo-Inositol/D-Chiro-Inositol Ratio for PCOS — Ratio Comparison

Trial comparing seven different MI:DCI ratios (including DCI alone and 1:3.5, 2.5:1, 5:1, 20:1, 40:1, 80:1) in PCOS patients receiving 2 g of inositols twice daily for 3 months. Outcomes: ovulation, FSH, LH, SHBG, testosterone, HOMA index.

56 PCOS patients (8 per group); 3-month intervention.

The 40:1 MI:DCI ratio was the most effective at restoring ovulation and normalizing reproductive and metabolic parameters. DCI alone and ratios biased heavily toward DCI showed less favorable outcomes, supporting the modern 40:1 protocol.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses in 40:1 combinations.
Mild nausea, gas, or diarrhea at higher DCI doses.
High DCI doses alone (>1,200 mg/day) may impair oocyte quality — prefer 40:1 protocol.
Headache or dizziness reported occasionally.
Limited safety data in pregnancy beyond first-trimester PCOS continuation studies.

Important Drug interactions

Antidiabetic medications (metformin, insulin) — additive blood-sugar effects; monitor when combining.
Hormonal contraceptives — inositol therapy is often used to improve ovulation; effects on contraceptive reliability not well studied.
Letrozole and clomiphene — sometimes used together for fertility; data on combined use is emerging but generally favorable.
Lithium — theoretical inositol depletion antagonism; clinical relevance unclear.

Featured in these supplement guides

PCOS→

More Women's Health Ingredients

Women's Health
Chasteberry / Vitex (Vitex agnus-castus)
Chasteberry (Vitex agnus-castus) fruit extract is the most clinically studied herbal medic…
Women's Health
Libifem® (Fenugreek for Female Libido)
Libifem® is the SAME standardized fenugreek seed extract as Testofen® (Fenuside™ furostano…
Women's Health
Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)
Lactobacillus fermentum CECT5716 (commercialized as Lc40 and Hereditum®) is a probiotic st…
Women's Health
ERr 731® (Rheum rhaponticum extract)
ERr 731® is a standardized extract of Siberian rhubarb (Rheum rhaponticum) root produced b…

Explore Other Ingredients

Metabolic Health
Fenugreek
Fenugreek is an aromatic seed used both as a culinary spice and a supplement, best known f…
Cognitive
KSM-66®
KSM-66 is the most extensively studied branded ashwagandha (Withania somnifera) extract, m…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…

Related articles from our blog

📝 Article
The 7 Best Metabolic Health Supplements of 2026
Few corners of the supplement aisle are as confusing as "metabolic health." The phrase is real and useful, it means how…
📝 Article
Inositol for PCOS: Benefits, the 40:1 Ratio, and How to Take It
Inositol is one of the rare supplements that lives up to its reputation. It has become a staple of PCOS and women's-heal…
📝 Article
Supplements for Fertility: For Her and For Him
When a couple starts trying to conceive, supplements are often the first thing they reach for, and it is an area with re…

Frequently asked questions about D-Chiro-Inositol

What is D-chiro-inositol used for?

D-chiro-inositol (DCI) is a form of inositol used, usually alongside myo-inositol, for PCOS and insulin and blood-sugar support. The two are typically combined in a 40-to-1 myo-to-D-chiro ratio that mirrors the body's natural balance.

Why is D-chiro-inositol combined with myo-inositol?

The 40-to-1 ratio of myo-inositol to D-chiro-inositol matches the body's natural plasma ratio and is the form used in much of the PCOS research. Too much D-chiro-inositol alone may actually be counterproductive for ovarian function, so the ratio matters.

How much D-chiro-inositol should I take?

In the studied 40-to-1 combination, D-chiro-inositol is the small component (about 100 mg alongside 4 grams of myo-inositol). Follow product labeling, and prefer the combined ratio over high-dose D-chiro alone.

Is D-chiro-inositol safe?

It is generally well tolerated. Because it affects insulin and blood sugar, those on diabetes medication should monitor. Stick to the studied ratio, as very high D-chiro-inositol alone is not recommended for ovarian goals.

What is D-Chiro-Inositol?

D-chiro-inositol (DCI) is one of nine inositol stereoisomers and the rarer counterpart to myo-inositol (MI), which dominates in most tissues. The body converts MI to DCI tissue-specifically via insulin-stimulated epimerase activity, and DCI participates in inositol-phosphoglycan (IPG) second messengers downstream of in…

What is the recommended dosage of D-Chiro-Inositol?

The clinically studied dose is DCI alone: 600-1,200 mg/day (older trials). Modern 40:1 MI:DCI: 4 g myo-inositol + 100 mg D-chiro-inositol per day, divided. Always follow the product label and check with a healthcare provider for personal advice.

Is D-Chiro-Inositol safe, and does it have side effects?

For most healthy adults, D-Chiro-Inositol is well tolerated at studied doses. Reported effects can include: Generally well-tolerated at typical doses in 40:1 combinations. Mild nausea, gas, or diarrhea at higher DCI doses. It may also interact with some medications. D-Chiro-Inositol is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does D-Chiro-Inositol interact with any medications?

Possible interactions include: Antidiabetic medications (metformin, insulin) — additive blood-sugar effects; monitor when combining. Hormonal contraceptives — inositol therapy is often used to improve ovulation; effects on contraceptive reliability not well studied. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for D-Chiro-Inositol?

NutraSmarts rates the evidence for D-Chiro-Inositol as Moderate (3 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314-20. doi: 10.1056/NEJM199904293401703.PubMedUsed to support: Foundational NEJM trial — 44 obese PCOS women; DCI 1,200 mg/day for 6-8 weeks induced ovulation in 86% vs 27% on placebo, with reductions in serum testosterone, blood pressure, and triglycerides.
  2. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417-23. doi: 10.4158/EP.8.6.417.PubMedUsed to support: 20 lean PCOS women; DCI 600 mg/day for 6-8 weeks reduced plasma insulin and free testosterone, lowered blood pressure and triglycerides, and induced ovulation in 60% vs 20% on placebo.
  3. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223.PubMedUsed to support: 56 PCOS patients across seven MI:DCI ratios; the 40:1 ratio was most effective at restoring ovulation and normalizing reproductive/metabolic parameters over 3 months, supporting the modern combination protocol.
  4. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515-6. doi: 10.1016/j.fertnstert.2011.05.027.PubMedUsed to support: Commentary describing the 'D-chiro-inositol paradox' — high DCI doses can paradoxically worsen oocyte quality despite improving systemic insulin sensitivity, providing the rationale for the 40:1 MI:DCI ratio protocol.